Okalova J, Alexander JS, Patel SR, Branella GM, Barichello de Quevedo C, Baldwin WH, Prince C, Chandrakasan S, Brown HC, Doering CB, Spencer HT (2026) Antimetabolites synergize with antibody drug conjugate-based non-genotoxic conditioning facilitating hematopoietic stem cell-directed lentiviral gene therapy. Mol Ther Adv doi: 10.1016/j.omta.2026.201780
Objective: To investigate the hypothesis that anti-CD117-sap is not effective as a single non-genotoxic conditioning agent in hematopoietic stem and progenitor cells (HSPCs)-directed lentiviral vector gene therapy for hemophilia A due to a lack of deep HSPC depletion in the bone marrow (BM).
Summary: The authors demonstrated how conditioning with non-genotoxic conditioning ADCs, such as Anti-CD117-SAP, causes cycling of residual HSPCs in the BM niche. There is potential of repurposing antimetabolites into these non-genotoxic conditioning regimens when combined with immune suppression to further target ADC-induced cycling HSPCs and augment depletion in the BM prior to HSCT.
Usage: A conjugate with Streptavidin-Saporin and biotinylated CD117 was developed. Mice were conditioned with the conjugate at doses ranging from 0.5 to 1 mg/kg.
Related Products: Streptavidin-ZAP (Cat. #IT-27), Anti-CD117-SAP (Cat. #IT-83)